---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-079392"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:08:49.950127+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TransMedics provides tax valuation allowance impact: Q4 adjusted EPS $0.47

## Summary
- Released $103.3M U.S. tax valuation allowance in Q4, driving $83.8M net income tax benefit.
- Annual effective tax rate 2025 was (77.0)%; without allowance release it would have been 19.1%.
- Q4 pre-tax income $21.6M; reported net income $105.4M ($2.62 diluted EPS).
- Adjusted net income after 19.1% tax rate: $17.5M ($0.47 diluted EPS).
- Future quarters expected to have tax provision more in line with U.S. statutory rates.

## SEC filing metadata
- accession: 0001193125-26-079392
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000119312526079392/0001193125-26-079392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000119312526079392/d80286d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-079392
- JSON: https://secwatch.observer/filing/0001193125-26-079392.json
- Plain text: https://secwatch.observer/filing/0001193125-26-079392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.